Eight patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2039
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2043.
US 10,933,020
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
Sep 27, 2039
US 10,925,832
Compositions and Methods for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation
Sep 27, 2039
US 11,471,413
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
Sep 27, 2039
US 11,452,692
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
Sep 27, 2039
US 11,890,378
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
Sep 27, 2039
US 12,558,317
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
Oct 29, 2039
US 12,421,242
Substituted Tetrahydropyrrolo-Pyridinone Compounds and Their Use in Treating Medical Conditions
Dec 15, 2043
20262031203620412043
8 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2039 · High confidence
Also notable
Ends Nov 2040 · High confidence
Also notable
Ends Dec 2043 · Medium confidence
Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
US 10,933,020
The most cited patent in this portfolio, cited by 9 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Xanomeline Derivatives and Methods for Treating Neurological Disorders
US 11,534,434
Granted 2022. Computed term ends 2040.
Substituted Tetrahydropyrrolo-Pyridinone Compounds and Their Use in Treating Medical Conditions
US 12,421,242
Granted 2025. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 6, 2027The maintenance fee for Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation (US 11,890,378) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,925,832 | Compositions and Methods for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation In force · High confidence | In force | High confidence | |
| US 10,933,020 | Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation In force · High confidence | In force | High confidence | |
| US 11,452,692 | Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation In force · Low confidence | In force | Low confidence | |
| US 11,471,413 | Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation In force · Low confidence | In force | Low confidence | |
| US 11,890,378 | Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation In force · Low confidence | In force | Low confidence | |
| US 12,558,317 | Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation In force · Medium confidence | In force | Medium confidence | |
| US 11,534,434 | Xanomeline Derivatives and Methods for Treating Neurological Disorders In force · High confidence | In force | High confidence | |
| US 12,421,242 | Substituted Tetrahydropyrrolo-Pyridinone Compounds and Their Use in Treating Medical Conditions In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 8: 8 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.